News Center

ASCO 2025: DualityBio to present data from ADC pipeline in oral presentations at 2025 ASCO Annual Meeting

2025-04-24

Duality Bio (9606.HK) will present datafrom two studies evaluating the HER3 ADC candidate DB-1310 and B7H3 ADC candidate DB-1311/BNT324, which is being developed in collaboration with BioNTech SE, in Oral/Rapid Oral presentations. The abstracts will be released on the ASCO website on May 23, 2025 (US local time).

More

2025-04-15

DualityBio (9606.HK) Officially Lists on Hong Kong Stock Exchange, Embarking on a New Chapter
2025-04-07

Duality Bio Appoints Hua Mu as Global Chief Medical Officer
2025-01-13

Voluntary Annuoncement Cooperation Between 3SBio Inc. And Duality Biol Ogics In Respect Of Her2 Adc Drug
2025-01-08

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate
2024-12-31

Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene
2024-12-06

Duality Biologics and BioNTech Presented Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors at the ESMO Asia Congress 2024

Scan the code to follow DualityBio official wechat

Phone：021-2601 8730

Address：Full floor, 11th floor, tower a, Datang International Plaza,China

Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai